Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 2Phase 1/2 2Phase NA 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Blood Specimen Collection 15Exercise 11Standard of Care 9Behavior Therapy 8Surveys and Questionnaires 7Palliative Care 7Carboplatin 7Methods 6Early Intervention, Educational 6Surgical Procedures, Operative 5Practice Guidelines as Topic 5Paclitaxel 5Interviews as Topic 5Educational Status 5Diet Therapy 5Specimen Handling 4Salpingectomy 4Hyperthermic Intraperitoneal Chemotherapy 4Genetic Testing 4Genetic Counseling 4Drug Therapy 4Counseling 4Yoga 3Psychiatric Rehabilitation 3Music Therapy 3Magnetic Resonance Spectroscopy 3Laparoscopy 3Diathermy 3Cytoreduction Surgical Procedures 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Ovarian Neoplasms × oregovomab × Clear all
NCT00551265 2017-07-14

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

GOG Foundation

Phase NA Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡